NATCO Pharma Limited has secured a significant regulatory milestone with the approval from India's Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide injection in the domestic market. The company made this announcement on February 14, 2026, through a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements.

Product Launch and Market Entry

The pharmaceutical company plans to launch the generic Semaglutide injection in the Indian market in March 2026. This timeline indicates a swift market entry strategy following the regulatory approval.

Therapeutic Application

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. This approval allows NATCO Pharma to enter the competitive diabetes treatment segment with a generic version of this important therapeutic agent.

Company Profile and Manufacturing Capabilities

NATCO Pharma Limited operates as a research and development-oriented, science-driven pharmaceutical company with a strong focus on oncology in targeted therapies for the domestic market. The company also concentrates on limited competition molecules in the US market.

Manufacturing and Regulatory Infrastructure

The company's manufacturing capabilities include:

• 9 manufacturing sites across India
• 2 dedicated R&D facilities
• Regulatory approvals from multiple international authorities including U.S. FDA, Brazil ANVISA, Health Canada, and WHO
• Market presence in over 50 global markets

Business Segments

NATCO Pharma's diversified portfolio encompasses multiple pharmaceutical segments:

• Generic and branded pharmaceuticals
• Specialty pharmaceuticals
• Active pharmaceutical ingredients
• Crop protection products

This CDSCO approval for Semaglutide represents another addition to NATCO Pharma's expanding pharmaceutical portfolio, particularly strengthening its position in the diabetes treatment market segment in India.

Natco Pharma announced its unaudited consolidated financial results for the quarter ended December 31, 2025, demonstrating steady performance with revenue growth and sustained profitability. The pharmaceutical company reported consolidated total revenue of ₹705.4 crore for Q3FY26, marking an increase from ₹651.1 crore recorded in the corresponding quarter of the previous year.

Financial Performance Highlights

The company's financial metrics for Q3FY26 showed robust operational performance across key parameters:

For the nine months ended December 31, 2025, the company reported total income of ₹35,590 million compared to ₹34,967 million in the corresponding period last year. Net profit for the nine-month period stood at ₹11,495 million against ₹14,774 million in the previous year.

Segment-wise Revenue Performance

The company's business segments showed varied performance during Q3FY26:

The pharmaceuticals segment contributed ₹6,189 million to revenue, while agro chemicals generated ₹284 million during the quarter.

Board Decisions and Corporate Actions

The Board of Directors approved several significant decisions during their meeting held on February 12, 2026:

Dividend Declaration:

• Third interim dividend of ₹1.50 per equity share (75%) for FY2025-26
• Record date: February 18, 2026
• Payment date: February 26, 2026

Key Appointments:

• Mr. Amit Parekh appointed as Chief Financial Officer effective February 13, 2026
• Mr. Kalakuntla Srinivas Rao appointed as Executive Vice President – Pharma Division
• Superannuation of Mr. S. V. V. N. Appa Rao as CFO effective February 12, 2026

Regulatory Compliance and Publications

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its quarterly results in leading newspapers on February 13, 2026. The publications appeared in Business Line, Financial Express, and Nava Telangana, providing comprehensive disclosure of the unaudited financial results and dividend notice.

Strategic Developments

The company announced plans to incorporate a wholly owned subsidiary in Chile named NATCO Pharma Chile SPA with an investment of up to US$ 3,00,000. Additionally, the Board approved the re-constitution of the Environmental, Social and Governance Committee and Risk Management Committee effective February 13, 2026.

Associate Company Performance

Natco Pharma's associate company, Adcock Ingram Holdings Limited in South Africa, contributed ₹109 million as share of profit during the quarter. The acquisition of 35.75% stake in Adcock Ingram was completed on November 11, 2025, for a total consideration of ZAR 3,873 million (USD 225 million).

Re-appointments and Governance

The Board recommended re-appointment of key directors for one-year terms effective April 1, 2026:

• Sri Venkaiah Chowdary Nannapaneni as Chairman & Managing Director
• Sri Rajeev Nannapaneni as Vice Chairman & Chief Executive Officer
• Sri Potluri Sivaramakrishna Prasad as Director and Executive Vice President
• Dr. Donthineni Linga Rao as Director & President (Technical Affairs)

These re-appointments are subject to shareholder approval through postal ballot.